Wave Life Sciences (WVE) Net Cash Flow (2014 - 2026)
Wave Life Sciences' (WVE) quarterly Net Cash Flow came in at -$176.7 million in Q2 2026, down 410.34% YoY from $56.9 million in Q2 2025, and down 207.51% on a QoQ basis from -$57.5 million in Q1 2026.
Wave Life Sciences (WVE) Net Cash Flow (2014 - 2026) Analysis & Trends
Wave Life Sciences (WVE) has 13 years of Net Cash Flow data on file, last reported at -$176.7 million in Q2 2026.
- Quarterly Net Cash Flow fell 410.34% year-over-year to -$176.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $159.5 million (up 192.94% YoY) and the FY2025 annual result came in at $300.0 million, up 194.35% from the prior year.
- Net Cash Flow eased to -$176.7 million in Q2 2026, from -$57.5 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $405.9 million in Q4 2025 to a low of -$176.7 million in Q2 2026.
- A 5-year average of $12.1 million and a median of -$22.7 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2025 — Net Cash Flow jumped 4737.5% — and 2026, when it plunged 410.34%.
- Tracing WVE's Net Cash Flow over 5 years: stood at -$8.5 million in 2022, then soared by 806.46% to $60.4 million in 2023, then plunged by 114.5% to -$8.8 million in 2024, then jumped by 4737.5% to $405.9 million in 2025, then slumped by 143.53% to -$176.7 million in 2026.
- The last three Net Cash Flow figures came in at -$176.7 million (Q2 2026), -$57.5 million (Q1 2026), and $405.9 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Wave Life Sciences | 1.05 Bn | 677.62 Mn | - | -176.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -176.71 Mn |
| Jun 30, 2026 | -176.71 Mn |
| Mar 31, 2026 | -57.46 Mn |
| Mar 31, 2026 | -57.46 Mn |
| Dec 31, 2025 | 405.92 Mn |
| Dec 31, 2025 | 405.92 Mn |
| Sep 30, 2025 | -12.22 Mn |
| Sep 30, 2025 | -12.22 Mn |
| Jun 30, 2025 | -34.63 Mn |
| Jun 30, 2025 | -34.63 Mn |
| Mar 31, 2025 | -59.05 Mn |
| Mar 31, 2025 | -59.05 Mn |
| Dec 31, 2024 | -8.75 Mn |
| Dec 31, 2024 | -8.75 Mn |
| Sep 30, 2024 | 156.89 Mn |
| Sep 30, 2024 | 156.89 Mn |
| Jun 30, 2024 | -26.87 Mn |
| Jun 30, 2024 | -26.87 Mn |
| Mar 31, 2024 | -19.34 Mn |
| Mar 31, 2024 | -19.34 Mn |